CAPITOL SOLUTIONS for AMGEN USA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
H.R. 1908 a bill to provide for patent reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CURTIS | LEGISLATIVE ASSISTANT, REP. STRICKLAND |
| DANIEL C TATE | N/A |
Budget/Appropriations BUD
S.Con.Res. 21, The Budget Resolution, and its authorization levels for SCHIP, Medicare, and Medicaid
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CURTIS | LEGISLATIVE ASSISTANT, REP. STRICKLAND |
| DANIEL C TATE | N/A |
Health Issues HCR
H.R. 1956 To amend the Public Health Service Act to provide for the approval of similar biological products H.R. 1038 provide for the licensing of comparable and interchangeable biological products
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CURTIS | LEGISLATIVE ASSISTANT, REP. STRICKLAND |
| DANIEL C TATE | N/A |
Medicare/Medicaid MMM
Medicare reimbursement and coverage issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CURTIS | LEGISLATIVE ASSISTANT, REP. STRICKLAND |
| DANIEL C TATE | N/A |
Food Industry (safety, labeling, etc.) FOO
The FDA’s issuance of a black box warning for erythropoietin stimulating agents H.R. 2900 To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the post-market authorities of the Food and Drug Administration with respect to the safety of drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CURTIS | LEGISLATIVE ASSISTANT, REP. STRICKLAND |
| DANIEL C TATE | N/A |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.